Curanex Pharmaceuticals
Curanex Pharmaceuticals is a developmental-stage pharmaceutical company discovering, developing, and commercializing botanical drugs for inflammatory and other serious diseases. Its lead candidate, Phyto-N, is being advanced across ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout, with a 2026 pipeline expansion into cancer cachexia and advanced cancer supportive care. The company completed GMP manufacturing and toxicology milestones supporting a planned Q4 2026 IND submission for ulcerative colitis. Curanex (formerly Fordman Pharma, renamed November 2023) listed on Nasdaq in August 2025 at $4.00 per share and implemented a 1-for-20 reverse stock split effective August 20, 2026 to maintain listing compliance, reducing shares outstanding to approximately 1.57 million.
Company Info
Upcoming Milestones & Key Dates
Planned IND submission for Phyto-N in ulcerative colitis
1-for-20 reverse stock split effective (listing compliance; ~1.57M shares outstanding post-split)
Clinical Development Pipeline
Phyto-N
Target: Botanical drug formulation for inflammatory diseasePhyto-N
Target: Botanical drug formulationPhyto-N
Target: Botanical drug formulationRecent News
No recent news updates available for this company.
Leadership Team
Jun Liu
Chief Executive Officer, President and Chairman
Wanjun Zhang
Chief Financial Officer and Treasurer
Dr. Liqin Xie, Ph.D.
Chief Operating Officer
Dr. Ning Zhang, Ph.D.
Chief Technology Officer